CyDex Inc., of Overland Park, Kan., appointed Jose Rodriguez vice president of business development.
DNAPrint Genomics Inc., of Sarasota, Fla., appointed Barbara Handelin director of diagnostics of its subsidiary, DNAPrint Pharmaceuticals Inc.
Durect Corp., of Cupertino, Calif., appointed Harry Guy vice president of engineering and safety and promoted Andrew Miksztal to vice president of pharmaceutical research and development. Also, Thomas McCracken was named vice president and chief patent counsel, and Schond Greenway was promoted to vice president, investor relations and strategic planning.
Endo Pharmaceuticals Holdings Inc., of Chadds Ford, Pa., appointed John Delucca to its board.
Exagen Diagnostics Inc., of Albuquerque, N.M., appointed Robert Mignatti president and chief operating officer.
Galapagos, of Saffron Walden, UK, appointed Angus MacLeod director of medicinal chemistry at the service division BioFocus.
Genentech Inc., of South San Francisco, promoted Ian Clark, David Ebersman and Patrick Yang to executive vice president. It also appointed six vice presidents: Jennifer Cook for market development; Ashraf Hanna for alliance management and pipeline strategy support; Ann Lee for process development; James Miller for South San Francisco biochemical manufacturing; Quinton Oswald for sales and marketing, tissue growth and repair; and Robert Quinn for CIT business and science applications.
Genta Inc., of Berkeley Heights, N.J., appointed Per Lindell vice president of business development, and Lloyd Sanders vice president of sales and marketing.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed Susan Koppy senior vice president, business and corporate development.
ImmuneRegen BioSciences, of Scottsdale, Ariz., named Asa Hutchinson and James Robert Campbell senior advisers to its bioterrorism preparedness advisory board.
InNexus Biotechnology Inc., of Vancouver, British Columbia, appointed Jeff Morhet chief operating officer.